J&J receives subpoena for Natrecor marketing documents
Executive Summary
The Boston U.S. Attorney's office issues subpoena to Johnson & Johnson subsidiary Scios requesting documents related to the sales and marketing of its congestive heart failure drug Natrecor (nesiritide), the company announced July 20. The subpoena comes on the heels of a New England Journal of Medicine article by Eric Topol (Cleveland Clinic) asserting that Scios has conducted an "aggressive marketing campaign" to promote Natrecor for serial outpatient use (1"The Pink Sheet" July 18, 2005, p. 9)...
You may also be interested in...
J&J Natrecor “Dear Doctor” Letter Advises Against Outpatient Use
Administration of Johnson & Johnson/Scios' Natrecor (nesiritide) in the outpatient setting is an "unsupported use" of the congestive heart failure therapy, the company said in a letter to health care practitioners
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.